

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Re the Application of:) Group Art Unit: Not yet assigned
Cantrell et al.) Examiner: Not yet assigned
Serial No.: 10/585006)
Filed: June 28, 2006) CERTIFICATE OF MAILING) I HEREBY CERTIFY THAT THIS CORRESP
Atty. File No.: 1675 WO/US) BEING MAILED USING THE UNITED STA SERVICE AS FIRST CLASS MAIL TO: CO

Title: Two-phase Method For The Synthesis Of Selected Pyrazolopyrimidines

CERTIFY THAT THIS CORRESPONDENCE IS LED USING THE UNITED STATES POSTAL S FIRST CLASS MAIL TO: COMMISSIONER rs, po box 1450, Alexandria, va 22313-1450, ON JULY 17, 2006.

MICHELLE DE CORTE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with duties imposed by 37 CFR §1.56 and means for complying therewith according to 37 CFR §§1.97-1.98, the references listed on the attached Form PTO/SB/08A are called to the attention of the US Patent & Trademark Office in relation to the present application.

No representation is made that the cited references are the only art or that the citied references represents the best art. The Examiner is urged to consider all of the cited references and to make an independent evaluation of the teachings and materiality of each.

Since this correspondence is being submitted prior to a first Office Action on the merits, it is believed that no fee is due. However, if a fee is required for entry of this correspondence, please charge Deposit Account No. 13-1160.

Respectfully submitted,

Christine Rebman Cooke (Reg. No. 50,546) christine.cooke@tycohealthcare.com

Curre R. Cooke

314-654-3939

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Page work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control umber

TRADEMARK.		Complete if Known		
MOEN			Application Number	10/585006
INFORMATION DISCLOSURE		Filing Date	June 28, 2006	
	STATEMENT BY APPLICANT		First Named Inventor	CANTRELL et al.
			Art Unit	Not yet assigned
	(use as many sheets as nece	essarv)	Examiner Name	Not yet assigned
Sheet	1 of	2	Attorney Docket Number	1675 WO/US

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US 6852858	02-08-2005	Feher et al.	
	A2	US 6476223	11-05-2002	Tombari et al.	
	A3	US 6399621	06-04-2002	Dusza et al.	
	A4	US 5714607	02-03-1998	Padmanathan	
	A5	US 4626538	12-02-1986	Dusza et al.	
	A6	US 2003/0040522	02-27-2003	Korodi et al.	
	Α7	US 2002/0072605	06-13-2002	Tombari et al.	
			-		

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant	T⁵
Initials*	No.¹	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	- WIIVI-DD-1111	Document	Figures Appear	
	B1	WO 02/100828	12-19-2002	Korodi et al.		
	B2	WO 01/10868	02-15-2001	Gross et al.		
. <u>.</u>						
	<u> </u>					

Examiner	Date
	Considered
Signature I	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. sKind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known TO TRADEMAR **Application Number** 10/585006 INFORMATION DISCLOSURE June 28, 2006 Filing Date STATEMENT BY APPLICANT CANTRELL et al. First Named Inventor Art Unit Not yet assigned Not yet assigned **Examiner Name** (use as many sheets as necessary) **Attorney Docket Number** 1675 WO/US of Sheet

NON PATENT LITERATURE DOCUMENTS Francisco Cita Include name of the outbor (in CARITAL LETTERS) title of the article (when appropriate) title of				
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	'	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue		
		number(s), publisher, city and/or country where published.		
	C1	ALMANSA et al., Synthesis and SAR of a New Series of COX-2-Selective Inhibitors:		
		Pyrazolo[1,5-a]pyrimidines, J. Med. Chem. 2001, 44, pp. 350-361 XP-002330232		
	C2	AL-MOUSAWI[a] et al., Synthesis of New Pyrazolo[1,5-a]pyrimidines And Pyrazolo[3,4-b]pyridines		
		2001, J. Heterocyclic Chem., 38, pp. 989-991 XP002330233		
	C3	International Search Report dated 06-07-2005		
	00	monatorial observations of the second of the		
				
	-			
	1			
	 			
	1			
	 			
	l			

Examiner	Date
Signature	Considered

JUL 2 0 2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.